Longboard Pharmaceuticals Inc (LBPH) News

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for...

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

Form SC 14D9 - Solicitation, recommendation statements

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Kuehn Law Encourages PRMW, FBMS, EVRI, and LBPH Investors to Contact Law Firm

Kuehn Law Encourages PRMW, FBMS, EVRI, and LBPH Investors to Contact Law Firm PR Newswire NEW YORK, Oct. 15...

Form SC14D9C - Written communication relating to third party tender offer

Form 8-K - Current report

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK...

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy, adding a highly innovative and...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines...

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

First sites activated with a number of additional rapid-start sites being activated in the coming weeks Longboard Pharmaceuticals, Inc. (Nasdaq:...